Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2009-11-19
2011-11-15
Fetterolf, Brandon (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S183000
Reexamination Certificate
active
08058295
ABSTRACT:
The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and treatment of CFTR-mediated diseases and conditions. The compositions and pharmaceutical preparations of the invention may comprise one or more thiazolidinone compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients and/or adjuvants. The methods of the invention comprise, in certain embodiments, administering to a patient suffering from a CFTR-mediated disease or condition, an efficacious amount of a thiazolidinone compound. In other embodiments the invention provides methods of inhibiting CFTR that comprise contacting cells in a subject with an effective amount of a thiazolidinone compound. In addition, the invention features a non-human animal model of CFTR-mediated disease which model is produced by administration of a thiazolidinone compound to a non-human animal in an amount sufficient to inhibit CFTR.
REFERENCES:
patent: 4873255 (1989-10-01), Yoshioka et al.
patent: 4965155 (1990-10-01), Nishiguchi et al.
patent: 5856331 (1999-01-01), Bursten et al.
patent: 6380186 (2002-04-01), Howard
patent: 6403592 (2002-06-01), Howard
patent: 6423708 (2002-07-01), Gibbs et al.
patent: 7235573 (2007-06-01), Verkman et al.
patent: 2002/0049211 (2002-04-01), Sobolov-Jaynes et al.
patent: 2002/0049214 (2002-04-01), Gibbs et al.
patent: 2002/0052396 (2002-05-01), Bailey et al.
patent: 2002/0072519 (2002-06-01), Howard
patent: 2002/0091117 (2002-07-01), Howard
patent: 2002/0091118 (2002-07-01), Howard
patent: 2002/0091119 (2002-07-01), Howard
patent: 0434394 (1998-08-01), None
patent: 1-156752 (1989-06-01), None
patent: 1-172836 (1989-07-01), None
patent: 1-173065 (1989-07-01), None
patent: 98/14433 (1998-04-01), None
patent: 00/10573 (2000-03-01), None
patent: 02/04167 (2002-01-01), None
Abdel-Rahman et al., “Heterodiene Synthesis. I Reaction of 5-Arylidenerhodanine Derivatives with 1-Morpholinocyclohexene Enamine,”Synthetic Communications19(3&4):345-354, 1989.
Abdel-Rahman et al., “A Chemical Evidence Supporting the Formation of Dihydropyran Adducts from the Reaction of 5-Arylidenerhodanines with 1-Morpholoncyclohexene through Zwitterionic Intermediate,”Afindad L. 50(445):155-159, 1993.
Abdel-Rahman, “Dihydropyrans from the Heterodienic Reaction of 5-Arylidenerhodanine Derivatives with Isoprene,”Chem. Papers47(6):385-387, 1993.
Appendix C—Thiazolidinone Chemical Structure Search (Identified References), pp. 1-70, 2002.
Cabantchik et al., “Chemical probes for anion transporters of mammalian cell membranes,”Invited Reviews, The American Physiological Society, pp. C803-C827, 1992.
Edwards et al., “induction of a glibenclamide-sensitive K-current by modification of a delayed rectifier channel in rat portal vein and insulinoma cells,”Br. J. Pharmacol. 110:1280-1281, 1993.
El-Shafei et al., “Applications of Phase-Transfer Catalysis in Reactions with Rhodanine Derivatives,”Gazzetta Chimica Italiana120:197-201, 1990.
Gabriel et al., “Cystic Fibrosis Heterozygote Resistance to Cholera Toxin in the Cystic Fibrosis Mouse Model,”Science266:107-109, Oct. 7, 1994.
Gabriel et al., “A novel plant-derived inhibitor of cAMP-mediated fluid and chloride secretion,”The American Physiology Society, pp. G58-G63, 1999.
Galietta et al., “Novel CFTR Chloride Channel Activators Identified by Screening of Combinatorial Libraries Based on Flavone and Benzoquinolizinium Lead Compounds,”Journal of Biological Chemistry276(23):19723-19728, Jun. 8, 2001.
Gorbach et al., “Acute Undifferentiated Human Diarrhea in the Tropics,”The Journal of Clinical Investigations50:881-889, 1971.
Grubb et al., “Pathophysiology of Gene-Targeted Mouse Models for Cystic Fibrosis,”Physiology Reviews79:Suppl. S193-S214, Jan. 1999.
Gupta et al., “Synthesis and Fungitoxicity of Some 5-Substituted-3-Polynitrophenyl Rhodanines,”J. Indian Chem. Soc. LV:483-485, May 1978.
Hongre et al., “Effects of sulphonyllureas on cAMP-stimulated Cl transport via the cystic fibrosis gene product in human epithelial cells,”Pflugers Arch. 426:284-287, 1994.
Jayararnan et al., “Submucosal gland secretions in airways from cystic fibrosis patients have normal [Na+] and pH but elevated viscosity,”PNAS98(14):8119-8123, Jul. 3, 2001.
Khalil et al., “The Action of Arylamines on 3-Aryl-5-Arylmethylenerhodanines,”Revue Roumaine de Chirnie23(6):935-941, 1978.
Khan et al., “Synthesis and insecticidal activity of 5-amino-7-aryl-6-cyano-3-substituted-thiazolo[4,5-b]-2,3,4,7-tetrahydropyridine-2-thione and 7-aryl-cyano-3-substituted-2-thioxo-thiazolo [4,5-b]-2,3,4,5,6,7-hexahydropyridin-5-one,”Indian Journal of Chemistry37B:1069-1074, Oct. 1998.
Ladnaya et al., “Synthesis and properties of Thiazolidons-4 Obtained From Phenamine II. Thiasolidindions-2,4,”Luov Medical Institute, pp. 37-41, with English Abstract, 1972.
Lohi et al., “Upregulation of CFTR expression but not SLC26A3 and SLC9A3 in ulcerative colitis,”Am. J. Physiol. Gastrointest. Liver Physiol. 283:G567-G575, 2002.
Ma et al., “High-affinity activators of cystic fibrosis transmembrane conductance regulator (CFTR) chloride conductance identified by high-throughput screening”J. Biol. Chem. 277(40):37235-37241, Oct. 4, 2002. Originally published in Press as doi: 10.1074/jbc, M205932200 on Aug. 2, 2002.
Ma et al., “Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion,”The Journal of Clinical Investigation110(11):1651-1658, Dec. 2002.
Makhlouf et al., “New antimicrobial rhodanines,”Pharmazie. 51:430-431, 1996.
McDonough et al., “Novel Pore-Lining Residues in CFTR That Govern Permeation and Open-Channel Block,”Neuron13:623-634, Sep. 1994.
Noone et al., “‘CFTR-opathis’: disease phenotypes associated with cystic fibrosis transmembrane regulator gene mutations,”Respir. Res. 2:328-332, 2001.
Oi et al., “Identification in traditional herbal medications and confirmation by synthesis of factors that inhibit cholera toxin-induced fluid accumulation,”PNAS99(5):3042-3046, Mar. 5, 2002.
Omar et al., “The Role of Substituents at Position-3 on the Mode of Cleavage of 5-Arylmethylene-2, 4-dioxothiazolidines,”Journal f. prakt. Chemie. Band 331, Heft3:S393-S398, 1989.
Pilewslci et al., “Role of CFTR in Airway Disease,”Physiological Review79(Suppl. 1):S215-S255, Jan. 1999.
Rabe et al., “Cl−channel inhibition by glibenclamide is not specific for the CFTR-type Cl−channel,”Pflugers Arch-Eur J. Physiol. 429:659-662, 1995.
Rasola et al., “Volume-sensitive Chloride Currents in Four Epithelial Cell Lines Are Not Directly Correlated to the Expression of the MDR-1 Gene,”J. Biol. Chem. 269(2):1432-1436, Jan. 14, 1994.
Richardson et al., “Studies on the Genetic and Cellular Control of Sensitivity to Enterotoxins in the Sealed Adult Mouse Model,”Infection and Immunity54(2):522-528, Nov. 1986.
Roman, O.M. et al., “Synthesis and anti-inflammatory activity of 3-aryl-5-arylidene-2-thixothiazolidine-4-ones,”Farmatsevtichnii Zhurnal(Kiev) (3):56-59, 2002.
Roman, O.M. et al., “Synthesis and anti-inflammatory activity of 3-aryl-5-arylidene-2-thixothiazolidine-4-ones,”Farmatsevtichnii Zhurnal(Kiev) (3):56-59, 2002, English Translation.
Schultz et al., “Pharmacology of CFTR Chloride Channel Activity,”Physiological Reviews79(Suppl. 1):S109-S144, Jan. 1999.
Sheppard et al., “Effect of ATP-sensitive K+Channel Regulators on Cystic Fibrosis Transmembrane Conductance Regulator Chloride Currents,”J. Gen. Physiol. 100:573-591, Oct. 1992.
Tejchman et al., “Introduct
Ma Tonghui
Verkman Alan
Fetterolf Brandon
Pagonakis Anna
Seed IP Law Group PLLC
The Regents of the University of California
LandOfFree
Cystic fibrosis transmembrane conductance regulator protein... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cystic fibrosis transmembrane conductance regulator protein..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cystic fibrosis transmembrane conductance regulator protein... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4255581